Arcutis reports Q3 net loss $57M; submits NDA for roflumilast cream in plaque psoriasis

Arcutis Biotherapeutics, Inc.

2021-Q3 EPS reported -$2.75

Net loss of $57.0M ($1.14/sh) vs $38.2M ($1.01/sh) in Q3 2020; cash $368.8M.
Submitted NDA to FDA for roflumilast cream for plaque psoriasis based on Phase 3 DERMIS trials.
Initiated pivotal Phase 3 trial of roflumilast foam in scalp/body psoriasis; topline expected H2 2022.
Terminated Phase 2a trial of ARQ-252 in vitiligo due to inadequate local drug delivery.
R&D expense $40.6M vs $32.7M YoY; G&A expense $16.5M vs $5.6M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.